会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • 2,4- DIAMINO QUINAZOLINE AND PYRIDOPYRIMIDINE ESTER DERIVATIVES AS DIHYDROFOLATE REDUCTASE INHIBITORS
    • 2,4-二氨基喹唑啉和吡咯烷酮衍生物作为二氢叶酸还原酶抑制剂
    • WO2004020418A1
    • 2004-03-11
    • PCT/GB2003/003714
    • 2003-08-27
    • MELACURE THERAPEUTICS ABPETT, Christopher, PhineasHALLBERG, AndersGRAFFNER-NORDBERG, MalinBOMAN, ArneSEIFERT, Elisabeth
    • HALLBERG, AndersGRAFFNER-NORDBERG, MalinBOMAN, ArneSEIFERT, Elisabeth
    • C07D239/95
    • C07D239/95
    • The invention provides novel compounds of the formula 11: wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen or a group that liberates the free amine in vivo , for example -CO-alkyl, preferably -CO-C 1 -C 3 alkyl or pivalate; or -CO­haloalkyl, preferably -CO-C 1 -C 3 haloalkyl, most preferably -CO-C 1 -C 3 chloroalkyl; wherein W is; and @ denotes the points of attachment and wherein the ester can be located in either direction; wherein n and m are independently 0-5; wherein one but not both of X and Y can be nitrogen, or X is C-A and/or Y is C-B; wherein A and B are independently selected from hydrogen, alkyl optionally substituted with a halogen, an electron donor group such as amino, alkylamino, dialkylamino or hydroxy, or an electron acceptor group such as nitro, cyano, trihaloalkyl or amido, alkoxy or halogen; and pharmacologically acceptable salts thereof. Provided that when R 1 to R 4 are hydrogen, both X and Y are C-H, n is 1 and -(CH 2 ) n - is attached to the bridging oxygen of the ester group W, then m cannot be 0 or 1.
    • 本发明提供式11的新化合物:其中R 1,R 2,R 3和R 4独立地为氢或在体内释放游离胺的基团,例如-CO-烷基,优选-CO-C 1 -C 3烷基或特戊酸酯; 或-CO卤代烷基,优选-CO-C 1 -C 3卤代烷基,最优选-CO-C 1 -C 3氯代烷基; 其中W是; 和@表示连接点,并且其中酯可以位于任一方向上; 其中n和m独立地为0-5; 其中X和Y中的一个但不是二者可以是氮,或X是C-A和/或Y是C-B; 其中A和B独立地选自氢,任选被卤素取代的烷基,电子给体基团如氨基,烷基氨基,二烷基氨基或羟基,或电子受体基团如硝基,氰基,三卤代烷基或酰胺基,烷氧基或卤素; 及其药理学上可接受的盐。 假设当R1至R4为氢时,X和Y均为C-H,n为1, - (CH2)n-连接到酯基W的桥连氧上,则m不能为0或1。
    • 6. 发明申请
    • NOVEL AMINOGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS.
    • 新的氨基葡萄糖作为MELANOCORTIN受体配体。
    • WO2008071980A1
    • 2008-06-19
    • PCT/GB2007/004793
    • 2007-12-13
    • ACURE PHARMA ABPETT, Christopher, PhineasLUNDSTEDT, TorbjörnSEIFERT, ElisabethLEK, PerBOMAN, Arne
    • LUNDSTEDT, TorbjörnSEIFERT, ElisabethLEK, PerBOMAN, Arne
    • C07C281/18C07D339/08A61K31/155A61K31/385A61P29/00
    • C07D339/08C07C281/18C07C323/48
    • There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0,1,2 or 3, saturated or unsaturated; most preferably at least one of R 1 to R 5 represents halogen; at least one of R 1 , R 2 , R 3 , R 4 and R 5 is selected from -S-R or -COOR, or two or more Of R 1 -R 5 comprise a linking group such as -S-(CH2) m S-, where m is 1, 2 or 3 and R is selected from alkyl having 1 to 5 carbon atoms, cycloalkyl having 3-6 carbon atoms, hydroxy, and aryl having 6 to 10 carbon atoms, such groups being optionally substituted, and when R 1 is selected from -S-R, then at least one of R 2 , R 3 and R 5 is most preferably selected from halogen; and R 1 , R 2 , R 3 , R 4 and R 5 are otherwise the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and pharmacologically acceptable salts thereof. Compounds described have activity on the melanocortin receptors and have application in the treatment of a wide range of inflammatory, arthritic or central nerve regeneration conditions.
    • 描述了通式(I)的化合物及其异构体形式,其中n为0,1,2或3,饱和或不饱和; 最优选R 1至R 5中的至少一个表示卤素; R 1,R 2,R 3,R 4和R 5中的至少一个, / SUB>选自-SR或-COOR,或者R 1 -R 5中的两个或更多个包含连接基团,例如-S-(CH 2) 5 <>最优选选自卤素; 和R 1,R 2,R 3,R 4和R 5, 选自氢,卤素,具有1-5个碳原子的烷基,电子给体基团如具有1-5个碳原子的烷氧基或羟基,选自氰基,硝基,三氟烷基或酰胺的电子受体基团; 烷基氨基,苯甲酰氧基,硝酰基,苯基或磺基; 及其药理学上可接受的盐。 所描述的化合物对黑皮质素受体具有活性,并且可用于治疗广泛的炎性,关节炎或中枢神经再生条件。